Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in New York

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Risk Communication

For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge, empowering individuals to make informed decisions about their well-being. This legacy of accessible health information has built a foundation of trust and awareness, enabling the public to engage with complex medical topics as they emerge. In recent years, however, the focus has shifted from general health maintenance to specific, high-stakes exposures that carry significant legal and medical implications. One such area involves the widespread use of medications like Ozempic, originally developed for metabolic conditions, which has led to growing scrutiny of unintended side effects. Among these, gastroparesis—a condition affecting stomach muscle function—has become a central concern for patients and healthcare providers alike. This transition from general health education to targeted risk awareness is particularly critical in occupational settings, where workers may face prolonged exposure to pharmaceutical agents or their byproducts. For instance, manufacturing personnel, pharmacy staff, and healthcare workers handling these drugs could encounter unique hazards that extend beyond the patient population. Understanding the statute of limitations for potential claims, such as those related to Ozempic and gastroparesis in New York, now requires a nuanced appreciation of both medical history and occupational exposure pathways. This pivot underscores the need for updated protocols that bridge general health literacy with workplace-specific risk management.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or more invasive interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. However, this effect can become pathological in some patients, leading to gastroparesis. Reported adverse effects from clinical trials indicate that gastrointestinal reactions are common. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Risk Context

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which slows gastric motility. While this effect is intended to improve glycemic control, it can lead to excessive delay in gastric emptying, mimicking or exacerbating gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. Patients who experience persistent nausea, vomiting, or abdominal pain should be evaluated for gastroparesis. Regarding risk anchors, the adequacy of warnings on Ozempic's label is a critical consideration. The label does not explicitly list gastroparesis as a warning or caution. Instead, it includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also advises caution in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant in settlement considerations, as patients may argue that the risk was not adequately communicated.

Statute of Limitations for Ozempic Claims in New York

Settlement-related considerations for affected patients in New York involve the statute of limitations, which generally requires filing a lawsuit within a certain period after the injury is discovered or should have been discovered. For personal injury claims, New York law typically allows three years from the date of injury. However, the timeline between exposure to Ozempic and the development of gastroparesis can complicate this calculation. Patients should document the date they started Ozempic, the onset of symptoms, and the date of diagnosis. Legal counsel can help determine whether the claim falls within the statute of limitations. In summary, patients who developed gastroparesis after using Ozempic may have legal recourse, but they must act promptly to preserve their rights. The evidence from clinical trials shows a clear association between Ozempic and gastrointestinal adverse effects, including those consistent with gastroparesis. The lack of a specific warning on the label may strengthen claims of inadequate warnings. Affected individuals in New York should consult with an attorney experienced in pharmaceutical litigation to evaluate their case and ensure compliance with the statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in New York?

In New York, personal injury claims generally must be filed within three years from the date of injury. For Ozempic-related gastroparesis, the clock may start when the injury is discovered or should have been discovered. It is crucial to consult an attorney promptly to ensure compliance.

Does the Ozempic label warn about gastroparesis?

The Ozempic label does not explicitly list gastroparesis as a warning or caution. It includes gastrointestinal adverse reactions and hypersensitivity warnings, but the absence of a specific gastroparesis warning may be relevant in legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.